Cargando…

Profile of saxagliptin in the treatment of type 2 diabetes: focus on Japanese patients

Saxagliptin is a selective and potent dipeptidyl peptidase (DPP)-4 inhibitor, approved as an adjunct to diet and exercise to improve glycemic control in type 2 diabetes mellitus (T2DM) in the USA on July 2009, and had been launched globally in over 86 countries by September 2013. In patients with T2...

Descripción completa

Detalles Bibliográficos
Autores principales:	Konya, Hiroyuki, Yano, Yuzo, Matsutani, Satoshi, Tsunoda, Taku, Ikawa, Takashi, Kusunoki, Yoshiki, Matsuo, Toshihiro, Miuchi, Masayuki, Katsuno, Tomoyuki, Hamaguchi, Tomoya, Miyagawa, Jun-ichiro, Namba, Mitsuyoshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2014
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4103926/ https://www.ncbi.nlm.nih.gov/pubmed/25050065 http://dx.doi.org/10.2147/TCRM.S46076

Ejemplares similares

Effects of combination therapy with mitiglinide and voglibose on postprandial plasma glucose in patients with type 2 diabetes mellitus
por: Konya, Hiroyuki, et al.
Publicado: (2013)

Very Short-Term Effects of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin on the Secretion of Insulin, Glucagon, and Incretin Hormones in Japanese Patients with Type 2 Diabetes Mellitus: Analysis of Meal Tolerance Test Data
por: Murai, Kazuki, et al.
Publicado: (2014)

Incretin responses to oral glucose load in Japanese non-obese healthy subjects
por: Nagai, Etsuko, et al.
Publicado: (2011)

Postabsorptive hyperglucagonemia in patients with type 2 diabetes mellitus analyzed with a novel enzyme‐linked immunosorbent assay
por: Matsuo, Toshihiro, et al.
Publicado: (2015)

Effects of Switching from Insulin Glargine or Detemir to Insulin Degludec in Patients with Type 1 Diabetes Mellitus
por: Kusunoki, Yoshiki, et al.
Publicado: (2013)

Effects of the naturally‐occurring disaccharides, palatinose and sucrose, on incretin secretion in healthy non‐obese subjects
por: Maeda, Aya, et al.
Publicado: (2013)

A case of type 1 diabetes mellitus with which localized insulin allergy was markedly alleviated by switching to insulin glulisine
por: Watanabe, Kahori, et al.
Publicado: (2016)

Association of time in range with hemoglobin A1c, glycated albumin and 1,5‐anhydro‐d‐glucitol
por: Ohigashi, Mana, et al.
Publicado: (2020)

Medium-Term Effects of Insulin Degludec on Patients with Type 1 Diabetes Mellitus
por: Nakae, Rie, et al.
Publicado: (2014)

Comparison of efficacy of concomitant administration of mitiglinide with voglibose and double dose of mitiglinide in patients with type 2 diabetes mellitus
por: Katsuno, Tomoyuki, et al.
Publicado: (2010)

Estimation of HbA1c response to sitagliptin by change in glycated albumin level for 2 weeks
por: Hamaguchi, Tomoya, et al.
Publicado: (2011)

Medium-Term Effect of Add-On Therapy with the DPP-4 Inhibitor, Sitagliptin, in Insulin-Treated Japanese Patients with Type 2 Diabetes Mellitus
por: Katsuno, Tomoyuki, et al.
Publicado: (2016)

Relationships between time in range, glycemic variability including hypoglycemia and types of diabetes therapy in Japanese patients with type 2 diabetes mellitus: Hyogo Diabetes Hypoglycemia Cognition Complications study
por: Kuroda, Norihiro, et al.
Publicado: (2020)

Association between low‐carbohydrate diets and continuous glucose monitoring‐derived time in ranges
por: Osugi, Keiko, et al.
Publicado: (2023)

Saxagliptin for type 2 diabetes
por: Chacra, Antonio R
Publicado: (2010)

Significance of Glycemic Variability in Diabetes Mellitus
por: Kusunoki, Yoshiki, et al.
Publicado: (2021)

Comparison of charges and resource use associated with saxagliptin and sitagliptin
por: Vaidya, Varun, et al.
Publicado: (2016)

Nonclinical and clinical pharmacology evidence for cardiovascular safety of saxagliptin
por: Pollack, Pia S., et al.
Publicado: (2017)

Evaluation of drug interactions of saxagliptin with sildenafil in healthy volunteers
por: Mansour, Rania Y., et al.
Publicado: (2022)

Efficacy and Safety of Saxagliptin as Add-On Therapy in Type 2 Diabetes
por: Neumiller, Joshua J.
Publicado: (2014)

Role of saxagliptin as monotherapy or adjunct therapy in the treatment of type 2 diabetes
por: Sharma, Morali D
Publicado: (2010)

Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data
por: Cobble, Michael E, et al.
Publicado: (2012)

Saxagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus
por: Kulasa, Kristen, et al.
Publicado: (2010)

Treatment of type 2 diabetes with saxagliptin: a pharmacoeconomic evaluation in Argentina
por: Elgart, Jorge F, et al.
Publicado: (2013)

Effects of saxagliptin on early microvascular changes in patients with type 2 diabetes
por: Ott, Christian, et al.
Publicado: (2014)

Utility of Saxagliptin in the Treatment of Type 2 Diabetes: Review of Efficacy and Safety
por: Jain, Rajeev
Publicado: (2015)

Saxagliptin Restores Vascular Mitochondrial Exercise Response in the Goto-Kakizaki Rat
por: Keller, Amy C., et al.
Publicado: (2015)

Saxagliptin and Metformin in Fixed Combination for the Treatment of Type 2 Diabetes in Adults
por: Minze, Molly G., et al.
Publicado: (2013)

Potency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor
por: Wang, Aiying, et al.
Publicado: (2012)

New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin
por: Gallwitz, Baptist
Publicado: (2010)

Clinical utility in the treatment of type 2 diabetes with the saxagliptin/metformin fixed combination
por: Panagoulias, George S, et al.
Publicado: (2014)

Clinical outcomes, not clinical utility, should be the major consideration for saxagliptin with or without metformin
por: Doggrell, Sheila A
Publicado: (2014)

Saxagliptin Efficacy and Safety in Patients With Type 2 Diabetes and Moderate Renal Impairment
por: Perl, Shira, et al.
Publicado: (2016)

The Use of Saxagliptin in People with Type 2 Diabetes in France: The Diapazon Epidemiological Study
por: Balkau, Beverley, et al.
Publicado: (2017)

Safety and efficacy of saxagliptin for glycemic control in non-critically ill hospitalized patients
por: Garg, Rajesh, et al.
Publicado: (2017)

Japanese Subarachnoid Aneurysm Trial of Neurosurgical Clipping versus Endovascular Coiling in 1863 Patients with Ruptured Intracranial Aneurysms
por: IRIE, Koreaki, et al.
Publicado: (2022)

Saxagliptin: A dipeptidyl peptidase-4 inhibitor in the treatment of type 2 diabetes mellitus
por: Dave, Darshan J.
Publicado: (2011)

Saxagliptin: A Selective DPP-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus
por: Shubrook, Jay, et al.
Publicado: (2011)

Effect of saxagliptin on the expression of HIF-1α in the liver of diabetic rats with fatty liver
por: Zhao, Qian, et al.
Publicado: (2018)

Saxagliptin but Not Sitagliptin Inhibits CaMKII and PKC via DPP9 Inhibition in Cardiomyocytes
por: Koyani, Chintan N., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_jaom807i64pohn7mnik4q0vnf7